Media Contact
+886-2-2627-2707+1-415-655-6603 info@altrubio.com
Media Contact
+886-2-2627-2707Podcast─Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio
Bioprocess Online─Overcoming Platform Inefficiencies In mAb Manufacturing
AltruBio to Present at the 2022 BIO International Convention
AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
BioProcess International─Manufacturing must align with new modalities to drive efficiency, AltruBio
AltruBio to Present at BioProcess International US West 2022
top